Repros Therapeutics Inc. (RPRX: Quote) announced Monday morning that it now plans to provide clinical results from the first pivotal study, ZA-301, of Androxal, in the treatment of secondary hypogonadism in Q3 2013 instead of Q2 2013.Repros Therapeutics has been steadily declining on above average volume since the open Monday and is now down 4.69 at $13.92, with volume at a 7-month high. The stock has dropped to a month and a half low and has fallen below its 50-day moving average.
Click here to receive FREE breaking news email alerts for REPROS THERAPEUTICS INC. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News